Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations. - Wikidata - wikimedia - TriplyDB

Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations.

Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations.

http://www.wikidata.org/entity/Q48580864

about

Role of P2X7 receptors in the development of diabetic retinopathy Advanced glycation: an important pathological event in diabetic and age related ocular disease A quantitative study of the effects of ionizing radiation on endothelial cells and capillary-like network formation.The impact of cataract on the quantitative, non-invasive assessment of retinal blood Flow.Medical treatment of diabetic retinopathy.Cellular signaling and potential new treatment targets in diabetic retinopathy.Robust Retinal Blood Vessel Segmentation Based on Reinforcement Local Descriptions Activation of Melanocortin Receptors MC 1 and MC 5 Attenuates Retinal Damage in Experimental Diabetic Retinopathy.Diabetic retinopathy is a neurodegenerative disorder.The Increased Transforming Growth Factor-β Signaling Induced by Diabetes Protects Retinal Vessels.Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes.Immunohistochemical study of vascular endothelial growth factor (VEGF), tumor suppressor protein (p53) and intercellular adhesion molecule (ICAM-1) in the conjunctiva of diabetic patients.Approach for a Clinically Useful Comprehensive Classification of Vascular and Neural Aspects of Diabetic Retinal Disease.Dietary intake and diabetic retinopathy: A systematic review.Increased D-serine in the aqueous and vitreous humour in patients with proliferative diabetic retinopathy.

P2860

Q26864242-93AF6C92-FE50-42A0-ACCF-DD36E031B215 Q28365776-FF711A99-6508-4DDD-8CD5-9E1A4A8625F7 Q33237162-A2097256-B192-4833-BFFC-47CB281C266B Q34034018-D33078CB-10B1-4187-B8C5-1E289C8FE601 Q35175679-2FCFF251-70DA-49FD-86FB-AB70FCB1196E Q37089750-C228FD6E-A58E-409C-AACE-6F38C40B933C Q37618219-7A7777C6-8D27-45B3-BEF6-EAD11DB371DB Q38439326-0C96607C-B9E7-41CE-A6A7-6876433188CB Q38730604-8086A914-6B8D-4B5A-AD28-76DB282DF371 Q42505245-2532B1C3-C8DE-4947-942D-9E7CCC2F2B77 Q46266238-A8621441-F414-4861-83DB-F95D810716C4 Q46944960-67CA1185-8F20-49DA-BC38-9E760A0CEFAA Q47710677-E5E3056C-9FDF-4707-A05C-196DD6928E70 Q48043505-18CEABB7-791E-42A3-8C94-0CCB88BDD5DD Q48879717-AA611DC5-8673-404B-AD30-C6CBB581B5D6

P2860

Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations.

http://www.wikidata.org/entity/Q48580864

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

Bowman Lecture 1998. Diabetic ...... nd therapeutic considerations.

@en

Bowman Lecture 1998. Diabetic ...... nd therapeutic considerations.

@nl

type

label

Bowman Lecture 1998. Diabetic ...... nd therapeutic considerations.

@en

Bowman Lecture 1998. Diabetic ...... nd therapeutic considerations.

@nl

prefLabel

Bowman Lecture 1998. Diabetic ...... nd therapeutic considerations.

@en

Bowman Lecture 1998. Diabetic ...... nd therapeutic considerations.

@nl

P1433

Q48580864-456F1851-D315-49C7-BA66-8C2BEDFA1222

P1476

Q48580864-E5646807-8803-452C-92FA-54C95EB9657D

P2093

Q48580864-61894316-044B-45E6-8843-1531A3F2C670

P2860

Q48580864-011F3E3D-7D9C-40F6-BF0A-52C2E0C1D109

Q48580864-025AD459-55D1-4B7F-B217-1CE398FAA802

Q48580864-071A5748-D7FE-420F-9CBA-A7B7D68C2C3D

Q48580864-0ADFB41C-58EE-4D38-A0CD-1DD6BFFC7E01

Q48580864-0C9B3C2C-BA13-4A48-B6B2-69B31AE095CB

Q48580864-0D509F8C-5C6F-4F91-8E57-C7D5D44345DA

Q48580864-0DB70307-ABFE-4DF6-ACEE-C85E1F45CB9F

Q48580864-103DAE70-904A-4415-9D54-D86953AE44D5

Q48580864-14114DAC-9061-4F4C-AE14-4CE9203AE3B7

Q48580864-1C98698E-5A80-4828-B7FE-F9A8BCFBFE3C

P2888

Q48580864-F9A60A78-5981-40F6-9EE4-5A1D5F59DF9E

P304

Q48580864-46F9E2D6-83C5-4F5D-82A9-BB4743DF5D76

P31

Q48580864-AB355391-93CA-43D1-988C-38FDB932D36B

P356

Q48580864-8609C1E3-C17B-4076-B093-9CB29E09F98F

P478

Q48580864-A7694FD0-8698-4D69-B96B-0718DC7D7FC0

P577

Q48580864-431DA94A-F50F-4A63-B982-F00CB30C50E9

P5875

Q48580864-0B786B0A-D41B-4EED-AB2D-539D9A27B451

P698

Q48580864-CBC7029B-7230-4ED8-BF01-4149F0B2E131

P356

P1433

P1476

Bowman Lecture 1998. Diabetic ...... nd therapeutic considerations.

@en

P2093

Archer DB

http://www.w3.org/2001/XMLSchema#string

P2860

A model for p53-induced apoptosis

Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics

Tobacco smoke is a source of toxic reactive glycation products

Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells

An agent cleaving glucose-derived protein crosslinks in vitro and in vivo

Vascular endothelial growth factor is a secreted angiogenic mitogen

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

P2888

P304

497-523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EYE.1999.130

http://www.w3.org/2001/XMLSchema#string

P478

13 ( Pt 4)

http://www.w3.org/2001/XMLSchema#string

P577

1999-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232791499

http://www.w3.org/2001/XMLSchema#string

P698

10692923

http://www.w3.org/2001/XMLSchema#string